Melanoma: An update on systemic therapies

Despite advances in early detection as described in part 1 of this continuing medical education series, melanoma continues to be a large contributor to cutaneous cancer-related mortality. In a subset of patients with unresectable or metastatic disease, surgical clearance is often not possible; therefore, systemic and local therapies are considered. The second article in this series provides dermatologists with an up-to-date working knowledge of the treatment options that may be prescribed by oncologists for patients with unresectable stage III, stage IV, and recurrent melanoma.

Automated summary

This article provides dermatologists with an up-to-date working knowledge of the treatment options prescribed by oncologists for patients with unresectable stage III, stage IV, and recurrent melanoma, who often cannot undergo surgical clearance due to the nature of their disease.